Objectives: We analyzed the bid approach of the Hungarian National Health Insurance Fund Administration (NHIFA) based on the results of two consecutive bids on colony stimulating factor (CSF).Methods: The Hungarian NHIFA database was used to analyze the changes in the number of patients treated with CSF and reimbursement paid by NHIFA, 12 months preceding and following the bids.Results: 13,974 patients received granulocyte-CSF treatment during 12 months prior to bidding. A 4.5% decrease (13,352) and further 1.3% decrease (13,185) in the total number of patients were observed during the first and second years, respectively. The annual health insurance subsidy paid during 12 months prior to the bids was. 7.49 billion Hungarian Forint (HUF) or 26.8 million Euro (EUR). In the first year following the bid, we found a 3.3 billion HUF (12.4 million EUR) decrease in health insurance subsidy (44% reduction). A further 7.9% reduction was observed during the second year, resulting in an annual health insurance subsidy of 3.59 billion HUF (12.1 million EUR).Conclusion: During the 2 years bid (public procurement procedure), the National Health Insurance Fund Administration managed to reduce the health insurance subsidy paid for the reimbursement of both original and biosimilar G-CSF products.

中文翻译：

---

匈牙利生物仿制粒细胞集落刺激因子的价格竞争和报销。

目的：我们基于连续两次对菌落刺激因子（CSF）的投标结果，分析了匈牙利国家健康保险基金管理局（NHIFA）的投标方法。方法：使用匈牙利NHIFA数据库分析了数量的变化。投标前后12个月接受CSF治疗并由NHIFA支付费用的患者。结果：13974例患者在投标前12个月接受了粒细胞CSF治疗。在第一年和第二年，患者总数分别减少了4.5％（13,352）和进一步减少了1.3％（13,185）。在投标之前的12个月内支付的年度健康保险补贴为。74.9亿匈牙利福林（HUF）或2680万欧元（EUR）。竞标后的第一年，我们发现了33亿匈牙利福林（12。健康保险补贴减少了400万欧元（减少了44％）。第二年进一步减少了7.9％，从而获得了35.9亿匈牙利福林（1210万欧元）的年度健康保险补贴。结论：在两年的招标（公共采购程序）中，国家健康保险基金管理局设法减少为原始和生物仿制药G-CSF产品报销而支付的健康保险补贴。